CO4940401A1 - Vacunas - Google Patents

Vacunas

Info

Publication number
CO4940401A1
CO4940401A1 CO98032854A CO98032854A CO4940401A1 CO 4940401 A1 CO4940401 A1 CO 4940401A1 CO 98032854 A CO98032854 A CO 98032854A CO 98032854 A CO98032854 A CO 98032854A CO 4940401 A1 CO4940401 A1 CO 4940401A1
Authority
CO
Colombia
Prior art keywords
oil
water
emulsion
adjuvant
composition
Prior art date
Application number
CO98032854A
Other languages
English (en)
Spanish (es)
Inventor
Nathalie Garcon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9711990.3A priority Critical patent/GB9711990D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO4940401A1 publication Critical patent/CO4940401A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
CO98032854A 1997-06-11 1998-06-09 Vacunas CO4940401A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine

Publications (1)

Publication Number Publication Date
CO4940401A1 true CO4940401A1 (es) 2000-07-24

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98032854A CO4940401A1 (es) 1997-06-11 1998-06-09 Vacunas

Country Status (17)

Country Link
EP (1) EP0999852A1 (fr)
JP (1) JP2002504106A (fr)
KR (1) KR20010013644A (fr)
CN (1) CN1260723A (fr)
AR (1) AR012959A1 (fr)
AU (1) AU728759B2 (fr)
BR (1) BR9810614A (fr)
CA (1) CA2293444A1 (fr)
CO (1) CO4940401A1 (fr)
GB (1) GB9711990D0 (fr)
HU (1) HU0004001A3 (fr)
IL (1) IL133126D0 (fr)
NO (1) NO996133L (fr)
PL (1) PL337488A1 (fr)
TR (1) TR199903048T2 (fr)
WO (1) WO1998056414A1 (fr)
ZA (1) ZA9804969B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1154790B1 (fr) * 1999-02-26 2004-10-20 Chiron S.r.l. Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PT1326638E (pt) 2000-10-18 2008-02-06 Glaxosmithkline Biolog Sa Vacinas contra cancros
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
CA2372181C (fr) * 1999-05-13 2012-04-17 American Cyanamid Company Preparations de combinaisons d'adjuvants
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DE60038567T2 (de) 1999-10-22 2009-05-14 Sanofi Pasteur Ltd., Toronto Modifiziertes gp100 und dessen verwendung
AT513913T (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
EP1435908A4 (fr) * 2001-09-13 2006-03-15 Korea Inst Sci & Tech Composition huileuse a base de paclitaxel, formulation pour chimio-embolisation, et procede d'elaboration
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
EP2277533B1 (fr) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methodes de vaccination contre le paludisme
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
CA2565500A1 (fr) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
TW200722101A (en) 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
TW201350129A (zh) 2005-12-22 2013-12-16 Glaxosmithkline Biolog Sa 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
SG170090A1 (en) 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
EA200900024A1 (ru) 2006-07-17 2009-06-30 Глаксосмитклайн Байолоджикалс С.А. Противогриппозная вакцина
BRPI0714326A2 (pt) 2006-07-18 2013-05-07 Glaxosmithkline Biolog Sa partÍcula de proteÍna imunogÊnica, composiÇço, uso de uma proteÍna ou de uma composiÇço, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncias de dna de codificaÇço do hospedeiro, processo para a produÇço de uma partÍcula, e, produto
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE037808T2 (hu) 2006-09-26 2018-09-28 Infectious Disease Res Institute Szintetikus adalékanyagot tartalmazó vakcina kompozíció
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US8137678B2 (en) 2006-11-03 2012-03-20 Intervet Inc. Canine lyme disease vaccine
WO2008107370A1 (fr) 2007-03-02 2008-09-12 Glaxosmithkline Biologicals S.A. Nouveau procédé et nouvelles compositions
EA201391788A1 (ru) 2007-06-26 2014-08-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
NZ583150A (en) 2007-08-13 2012-05-25 Glaxosmithkline Biolog Sa Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria
EP3118213A1 (fr) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Formes solubles de virus hendra et nipah glycoprotéine f et leurs utilisations
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036945A2 (fr) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Compositions thérapeutiques du type nano-émulsion et procédés pour les utiliser
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
CA2751379C (fr) 2009-02-10 2018-06-12 Novartis Ag Vaccins contre la grippe comportant des quantites reduites de squalene
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
MX360448B (es) 2009-06-05 2018-11-01 Infectious Disease Res Institute Adyuvantes sinteticos de glucopiranosil-lipido.
JP6110140B2 (ja) 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ナノエマルションワクチン
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
WO2012041669A1 (fr) 2010-09-27 2012-04-05 Crucell Holland B.V. Régime de vaccination de type amorce rappel hétérologue contre la malaria
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
SI2758432T1 (sl) 2011-09-16 2019-07-31 Ucb Biopharma Sprl Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013083753A2 (fr) 2011-12-07 2013-06-13 Institut Pasteur Identification d'un virus porcin de type paréchovirus et applications
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
WO2013173590A1 (fr) 2012-05-16 2013-11-21 Immune Design Corp. Vaccins contre le hsv-2
US20150152140A1 (en) 2012-06-06 2015-06-04 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
BR112015001313A2 (pt) 2012-07-24 2017-08-01 Sanofi Pasteur composições de vacina
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
KR101819803B1 (ko) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 혈소판 표적화 치료
WO2014083194A1 (fr) 2012-11-30 2014-06-05 Sanofi Pasteur Procédés d'induction d'anticorps
MX2015014431A (es) 2013-04-18 2016-06-02 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015063611A2 (fr) 2013-11-01 2015-05-07 University Of Oslo Variants d'albumine et utilisations de ceux-ci
WO2015070207A2 (fr) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Épitopes ama-1, anticorps, compositions et leurs procédés de production et d'utilisation
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
EP3069138B1 (fr) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
WO2015077442A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
US20160287696A1 (en) 2013-11-20 2016-10-06 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
CR20160369A (es) 2014-01-21 2016-10-05 Immune Desing Corp Composiciones para uso en el tratamiento de afecciones alérgicas
WO2015131053A1 (fr) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides dérivés de phl p, procédés et utilisations de ces derniers pour moduler une réponse immunitaire
KR101696514B1 (ko) * 2014-08-18 2017-01-24 서울대학교산학협력단 신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
BR112018067897A2 (pt) 2016-03-14 2019-04-24 Univ I Oslo imunoglobulinas modificadas com ligação de fcrn alterada
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
WO2017221072A2 (fr) 2016-06-21 2017-12-28 University Of Oslo Fragments de vaccin de liaison à hla et leurs utilisations
CA3034124A1 (fr) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Peptides de fusion avec des antigenes lies a des fragments courts de chaine invariante (cd74)
WO2018060288A1 (fr) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions et méthodes de traitement d'une infection par hpv persistante
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018232257A1 (fr) 2017-06-15 2018-12-20 Infectious Disease Research Institute Supports lipidiques nanostructurés et émulsions stables et leurs utilisations
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
WO2019048936A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules vaccinales
WO2019090238A1 (fr) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Vaccins et compositions immunogènes anti-zika, et leurs procédés d'utilisation
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
AU8336598A (en) 1998-12-30
NO996133D0 (no) 1999-12-10
TR199903048T2 (xx) 2000-08-21
BR9810614A (pt) 2000-09-12
HU0004001A2 (en) 2001-03-28
AU728759B2 (en) 2001-01-18
HU0004001A3 (en) 2001-07-30
NO996133L (no) 2000-01-26
JP2002504106A (ja) 2002-02-05
CN1260723A (zh) 2000-07-19
IL133126D0 (en) 2001-03-19
PL337488A1 (en) 2000-08-28
EP0999852A1 (fr) 2000-05-17
KR20010013644A (ko) 2001-02-26
WO1998056414A1 (fr) 1998-12-17
ZA9804969B (en) 1999-12-09
GB9711990D0 (en) 1997-08-06
CA2293444A1 (fr) 1998-12-17
AR012959A1 (es) 2000-11-22

Similar Documents

Publication Publication Date Title
KR970705403A (ko) 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant)
NZ545289A (en) Vaccine formulations comprising an oil-in-water emulsion
NO20031595D0 (no) Vaksinesammensetning
AR037196A1 (es) Telas compuestas que tienen regiones polimericas elasticas discretas
ES2096505T3 (es) Composicion cosmetica o dermatologica constituida por una emulsion de aceite en agua a base de globulos oleosos provistos de un recubrimiento de cristal liquido laminar.
BR9914160A (pt) Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
HRP20120136T1 (en) Immunogenic composition comprising an adjuvant
BR9813066A (pt) Revestimento isolante de calor, processo para produzì-lo, uso do mesmo, sistema de revestimento multicomponentes, e, pelìcula, em particular uma pelìcula adesiva
MX9404075A (es) Diente para zona interfacial de adaptador.
ITTO20010005A1 (it) Formulazione farmaceutica.
ES2191979T3 (es) Sistema de administracion de acido linoleico conjugado en preparaciones cosmeticas.
BR9912155A (pt) Implante, e, método de implantar o mesmo numa estrutura de tecido ósseo.
DE68906477T2 (de) Zubereitungen mit verzoegerter freisetzung sowie deren herstellung.
GT200000108A (es) Procedimiento para la obtencion de composiciones antibacteriales.
AT213932T (de) Mittel mit gesteuerter freisetzung, die eine umgekehrte micellare (l2) struktur oder eine normale micellare (l1) struktur bilden
MX9207378A (es) Composicion de tinta borrable e instrumento de escritura que emplea dicha composicion.
ES2160631T3 (es) Composiciones de retinoides para aplicacion topica.
DE69704733T2 (de) Antriebsstrangretarder mit Kugelrampen-betätigten Reibscheiben
AR031651A1 (es) Fluidos para perforacion y mantenimiento de pozos que contienen chitosan acuoso con una viscosidad aumentada
BR0017161A (pt) Dispositivo de iluminação, e, pelìcula óptica
ES2111784T3 (es) Lamina poliolefinica de capas multiples orientada, no sellable y transparente, procedimiento para su fabricacion y su utilizacion.
ES2140191T3 (es) Crema auto-espumante.
ES2127206T3 (es) Composicion acondicionadora de tejidos que contiene una mezcla de silicona emulsionada.
AR011985A1 (es) Emulsion de aceite-en-agua que comprende una fase aceitosa dispersada en una fase acuosa cuyos globulos de aceite tienen un tamano medio inferior a 150nm, su utilizacion, procedimiento para su peparacion, composicion de uso topico que esta constituida por dicha emulsion o comprende a dicha emulsion